Patients with advanced cancer take many medications considered unnecessary. Medication reconciliation should be performed routinely for these patients.

Approximately one in 10 unplanned hospitalizations of cancer patients is associated with an ADE. Prospective and population-based studies are warranted to evaluate their magnitude in oncology.

No abstract

Gabapentin is a low-cost strategy to improve complete control of CINV, specially delayed CINV control.

Background: Preclinical and retrospective studies suggest that beta-blockers are active against breast cancer. We carried out a systematic review and meta-analysis to assess the impact of beta-blockers on the outcomes of patients with earlystage breast cancer. Methods: A systematic literature search was performed to identify studies comparing outcomes of patients with earlystage breast cancer according to beta-blocker use (yes versus no). The primary endpoint was recurrence-free survival (RFS), defined as the occurrence of breast cancer recurrence or death. Secondary objectives were pathologic complete response (pCR), breast cancer recurrence, breast cancer-specific mortality and overall survival (OS). Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CIs) were extracted from each study and a pooled analysis with the random-effect model was conducted. The Higgins' I-squared test was used to quantify heterogeneity. Egger's test was applied to assess publication bias. All P values were two-sided and considered significant if 0.05. Results: Overall, 13 studies were included as follows: RFS (6), pCR (2), breast cancer recurrence (6), breast cancerspecific mortality (7) and OS (5). The use of beta-blockers was associated with a significant RFS improvement in the overall population (N ¼ 21 570; HR 0.73; 95% CI, 0.56-0.96; P ¼ 0.025) and in patients with triple-negative disease (N ¼ 1212; HR 0.53; 95% CI, 0.35-0.81; P ¼ 0.003). No significant differences in terms of pCR (N ¼ 1554; OR 0.77; 95% CI, 0.44-1.36; P ¼ 0.371), breast cancer recurrence (N ¼ 37 957; OR 0.66; 95% CI, 0.42-1.03; P ¼ 0.065), breast cancer-specific mortality (N ¼ 64 830; HR 0.77; 95% CI, 0.56-1.08; P ¼ 0.130) or OS (N ¼ 103 065; HR 1.03; 95% CI, 0.87-1.23; P ¼ 0.692) were observed according to beta-blocker use. Discussion: In this meta-analysis, beta-blocker use was associated with a longer RFS in patients with early-stage breast cancer, with a more pronounced effect observed in those with triple-negative disease. Beta-blockers arise as an interesting option to be explored in prospective studies for patients with early-stage breast cancer.